This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Jump to section
Related Articles
Cited By...
- Dosimetric Analysis of 177Lu-cG250 Radioimmunotherapy in Renal Cell Carcinoma Patients: Correlation with Myelotoxicity and Pretherapeutic Absorbed Dose Predictions Based on 111In-cG250 Imaging
- Impact of Rituximab Treatment on 90Y-Ibritumomab Dosimetry for Patients with Non-Hodgkin Lymphoma
- Enhancement of the Therapeutic Index: From Nonmyeloablative and Myeloablative toward Pretargeted Radioimmunotherapy for Metastatic Prostate Cancer
- Does Paclitaxel (Taxol) Given after 111In-Labeled Monoclonal Antibodies Increase Tumor-Cumulated Activity in Epithelial Cancers?
- High-Dose 131I-Tositumomab (Anti-CD20) Radioimmunotherapy for Non-Hodgkin's Lymphoma: Adjusting Radiation Absorbed Dose to Actual Organ Volumes
- Underestimation of Absorbed Dose to Kidney
- Enhanced Therapeutic Index of Radioimmunotherapy (RIT) in Prostate Cancer Patients: Comparison of Radiation Dosimetry for 1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-Tetraacetic Acid (DOTA)-Peptide versus 2IT-DOTA Monoclonal Antibody Linkage for RIT
- MIRD Pamphlet No. 19: Absorbed Fractions and Radionuclide S Values for Six Age-Dependent Multiregion Models of the Kidney
- 90Y-DOTA-hLL2: An Agent for Radioimmunotherapy of Non-Hodgkin's Lymphoma
- Metabolite Production in Patients with Lymphoma After Radiometal-Labeled Antibody Administration
- Radioimmunotherapy with 111In/90Y-2IT-BAD-m170 for Metastatic Prostate Cancer
- How Far Have We Come with Solid (Nonhematologic) Tumor Radioimmunotherapy?